T1	Claim 1811 1897	PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.
T2	Claim 1731 1810	The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.
T3	Premise 1603 1730	The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).
T4	Premise 1457 1602	Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).
T6	Premise 954 1120	IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.
T7	Premise 1121 1268	IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.
R1	Support Arg1:T3 Arg2:T2	
R2	Support Arg1:T3 Arg2:T1	
R3	Support Arg1:T4 Arg2:T1	
R4	Support Arg1:T7 Arg2:T2	
R5	Support Arg1:T6 Arg2:T2	
